Avantor Results Presentation Deck

Q4 performance Organic revenue Adjusted EBITDA growth Fully diluted adjusted EPS growth Free cash flow Adjusted Net Leverage avantor™ 14.9% 21.3% 57.2% $286M 4.0X - - - >20% growth in Biopharma, Healthcare & Government 800-900 bps COVID-19 tailwinds Volume leverage, commercial excellence, and productivity Mix benefits from strong proprietary product growth Strong operations and lower interest expense Full year adjusted tax rate of 22.9% vs. 26% (2019) Solid conversion, 152% of Adjusted Net Income Continued working capital discipline Down from 4.6x in Q4'19 In-line with long-term leverage target of 2-4X 6

View entire presentation